Clinical Trial Update: A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating the combination of Sintilimab, Ipilimumab, Cetuximab, and Dabrafenib in microsatellite-stable, BRAF V600E-mutated metastatic colorecta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Dabrafenib (Dabrafenib)
• Sintilimab (sintilimab)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: BRAF V600E, Colorectal Cancer | Phase 2 | Status: RECRUITING